Discover XORTX's Live Investor Session and Innovative Treatments

Join XORTX for an Exclusive Live Investor Webinar

XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) warmly invites investors to participate in an exciting live webinar and Q&A session scheduled for September 10 at 4:15 PM ET. This virtual event represents a unique opportunity for stakeholders to engage directly with the company's leadership and learn about pioneering therapies targeting gout and progressive kidney disease.

Insightful Discussion Led by Dr. Allen Davidoff

The webinar will be led by Dr. Allen Davidoff, the founder and CEO of XORTX, who is passionate about the company’s mission to address critical health needs through innovative treatments. Dr. Davidoff will provide an overview of XORTX's primary project, XRx-026 (XORLO™), aimed at those intolerant to allopurinol, a common treatment for gout. With plans for a New Drug Application (NDA) submission in the near future, XORTX anticipates that XORLO™ could tap into a significant market opportunity valued at an impressive USD $700 million annually.

XORTX's Commitment to Advancing Kidney Health

In addition to XORLO™, Dr. Davidoff will highlight the company's development of XRx-008, a promising treatment for autosomal dominant polycystic kidney disease (ADPKD). This candidate holds potential for orphan designation and exemplifies XORTX’s broader commitment to combating renal conditions. The presentation will also briefly cover additional innovative projects in their pipeline, including XRx-101 for acute kidney injury and XRx-225 targeting diabetic nephropathy.

Engage in a Live Q&A Session

Following the presentation, attendees will have the chance to engage in a live Q&A session with XORTX management. This interactive component allows participants to ask questions and gain deeper insights into the company’s strategies and product development efforts.

Register for the Free Webinar

Interested investors can register for the webinar at no cost. Ensure your spot by accessing the registration page. Additionally, questions can be submitted in advance or during the live session.

About XORTX Therapeutics Inc.

XORTX is devoted to transforming the landscape of kidney health through its clinically advanced pharmaceutical products. The company focuses on three main areas: treating gout with XRx-026, addressing ADPKD with XRx-008, and providing solutions for acute kidney injuries with XRx-101. Further, they’re in the process of developing XRx-225, a promising candidate for managing Type 2 diabetic nephropathy.

Innovation and Patient Focus

At XORTX, innovation is at the heart of everything they do. The company is dedicated to developing treatments that target abnormal purine metabolism and inhibit the production of uric acid, significantly improving patients' quality of life. With a strong vision, XORTX aims to address the unmet needs of patients suffering from gout and other impactful conditions.

Contact Information

If you would like more information or have any inquiries, please reach out to the company representatives listed below:

Allen Davidoff, CEO – adavidoff@xortx.com or +1 403 455 7727

Nick Rigopulos, Director of Communications – nick@alpineequityadv.com or +1 617 901 0785

For inquiries related to the webinar, please contact: XRTX@redchip.com or +1 407 644 4256

Frequently Asked Questions

What is the purpose of the XORTX investor webinar?

The webinar aims to provide insights into XORTX's innovative therapies and connect investors with the company's leadership.

Who will be presenting during the webinar?

The presentation will be led by Dr. Allen Davidoff, the CEO of XORTX Therapeutics Inc.

How can I submit questions for the Q&A session?

Questions can be submitted prior to or during the live Q&A session via the registration platform.

What products are being developed by XORTX?

XORTX is developing treatments for gout, ADPKD, and acute kidney injuries, among other conditions.

How can I register for the webinar?

You can register for the free webinar through the provided registration link in the announcement.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.